Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer.

@article{Vergez2010PreclinicalAC,
  title={Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer.},
  author={S{\'e}bastien Vergez and Jean-Pierre Delord and Fabienne Thomas and Philippe Rochaix and Olivier Caselles and Thomas Filleron and S{\'e}v{\'e}rine Brillouet and Pierre Canal and Frederic Courbon and Ben Cuider Allal},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2010},
  volume={16 17},
  pages={4434-45}
}
PURPOSE There is a clinical need to identify predictive markers of the responses to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI). Deoxy-2-[(18)F]fluoro-d-glucose positron emission tomography with computed tomography ((18)FDG-PET/CT) could be a tool of choice for monitoring the early effects of this class of agent on tumor activity. EXPERIMENTAL DESIGN Using models of human head and neck carcinoma (CAL33 and CAL166 cell lines), we first tested in vitro and in vivo… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies.

American journal of nuclear medicine and molecular imaging • 2015
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…